Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-Induced B-Cell Acute Lymphoblastic Leukemia.
Yang L, Qiu Q, Tang M, Wang F, Yi Y, Yi D, Yang Z, Zhu Z, Zheng S, Yang J, Pei H, Zheng L, Chen Y, Gou L, Luo L, Deng X, Ye H, Hu Y, Niu T, Chen L.
Yang L, et al. Among authors: zheng s, zheng l.
Clin Cancer Res. 2019 Dec 15;25(24):7527-7539. doi: 10.1158/1078-0432.CCR-19-0516. Epub 2019 Aug 22.
Clin Cancer Res. 2019.
PMID: 31439580